Abstract
AbstractTargeted therapies, such as endocrine therapies (ET), can exert selective pressure on cancer cells and promote adaptations that confer treatment resistance. In this study, we show that ET resistance in breast cancer drives radiation resistance through reprogramming of DNA repair pathways. We also show that pharmacological bromodomain and extraterminal domain inhibition reverses pathological DNA repair reprogramming in ET-resistant breast tumors and overcomes resistance to radiation therapy.
Funder
U.S. Department of Defense
U.S. Department of Health & Human Services | National Institutes of Health
Cancer Prevention and Research Institute of Texas
Publisher
Springer Science and Business Media LLC